JP Morgan Chase
NKTR icon

JP Morgan Chase’s Nektar Therapeutics NKTR Stock Holding History

JP Morgan Chase’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7
Closed -$1K – 6741
2022
Q1 		$1K Sell
7
-3,580
-100% -$530K ﹤0.01% 6487
2021
Q4 		$727K Buy
3,587
+767
+27% +$166K ﹤0.01% 4601
2021
Q3 		$760K Hold
2,820
– – ﹤0.01% 4489
2021
Q2 		$726K Hold
2,820
– – ﹤0.01% 4488
2021
Q1 		$846K Buy
+2,820
New +$878K ﹤0.01% 4348
2019
Q4 		– Sell
-1,253
Closed -$342K – 5792
2019
Q3 		$342K Hold
1,253
– – ﹤0.01% 4357
2019
Q2 		$652K Sell
1,253
-2,067
-62% -$1.04M ﹤0.01% 4103
2019
Q1 		$1.67M Buy
3,320
+653
+24% +$387K ﹤0.01% 3456
2018
Q4 		$1.31M Buy
+2,667
New +$1.61M ﹤0.01% 3568
2018
Q3 		– Sell
-94,040
Closed -$68.9M – 5762
2018
Q2 		$68.9M Buy
+94,040
New +$108M 0.01% 819
2018
Q1 		– Sell
-3,800
Closed -$3.4M – 5545
2017
Q4 		$3.4M Buy
+3,800
New +$2.25M ﹤0.01% 2979

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase's NKTR Position: Q1 2026 in Review

JP Morgan Chase increased its Nektar Therapeutics (NKTR) stake by 59% in Q1 2026, buying an estimated $5.08M and bringing the position to 240,102 shares worth $15.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2289.

JP Morgan Chase first reported a position in NKTR in Q2 2013 and has held it in 52 quarters since. The position peaked at $135M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • JP Morgan Chase held 240,102 shares of Nektar Therapeutics worth $15.7M as of Q1 2026.
  • JP Morgan Chase bought 89,298 Nektar Therapeutics shares in Q1 2026, an estimated $5.08M.
  • Nektar Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2289 holding.
  • JP Morgan Chase first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • JP Morgan Chase's Nektar Therapeutics position peaked at $135M in Q1 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.